Like the prophylactic efficacy, the therapeutic B16-LX/IL(15 + 7) vaccine significantly inhibited B16-F10 tumor growth compared to the B16-LX/RFP vaccine, demonstrating the antitumor role of dual cytokines. Here, IL15 is linked to neoplasm.